Screening of cell cycle fusion proteins to identify kinase signaling networks

References

• Nurse P. Universal control mechanism regulating onset of M-phase. Nature 1990; 344:503-8; PMID:2138713; http://dx.doi.org/10.1038/344503a0
   PubMed Web of Science ®Google Scholar
• Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71:543-6; PMID:1423612; http://dx.doi.org/10.1016/0092-8674(92)90586-2
   PubMed Web of Science ®Google Scholar
• Reed SI. The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol 1992; 8:529-61; PMID:1476805; http://dx.doi.org/10.1146/annurev.cb.08.110192.002525
   PubMedGoogle Scholar
• Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73:1059-65; PMID:8513492; http://dx.doi.org/10.1016/0092-8674(93)90636-5
   PubMed Web of Science ®Google Scholar
• Morgan DO. Principles of CDK regulation. Nature 1995; 374:131-4; PMID:7877684; http://dx.doi.org/10.1038/374131a0
   PubMed Web of Science ®Google Scholar
• Pines J. Cyclins and their associated cyclin-dependent kinases in the human cell cycle. Biochem Soc Trans 1993; 21:921-5; PMID:8132094
   PubMed Web of Science ®Google Scholar
• Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8:9-22; PMID:8288131; http://dx.doi.org/10.1101/gad.8.1.9
   PubMed Web of Science ®Google Scholar
• Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massagué J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66; PMID:8033212; http://dx.doi.org/10.1016/0092-8674(94)90572-X
   PubMed Web of Science ®Google Scholar
• Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996; 382:325-31; PMID:8684460; http://dx.doi.org/10.1038/382325a0
   PubMed Web of Science ®Google Scholar
• Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570-3; PMID:7990932; http://dx.doi.org/10.1038/372570a0
   PubMed Web of Science ®Google Scholar
• Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79:487-96; PMID:7954814; http://dx.doi.org/10.1016/0092-8674(94)90257-7
   PubMed Web of Science ®Google Scholar
• Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267:1018-21; PMID:7863327; http://dx.doi.org/10.1126/science.7863327
   PubMed Web of Science ®Google Scholar
• Poon RY, Toyoshima H, Hunter T. Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 1995; 6:1197-213; PMID:8534916; http://dx.doi.org/10.1091/mbc.6.9.1197
   PubMed Web of Science ®Google Scholar
• Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996; 272:877-80; PMID:8629023; http://dx.doi.org/10.1126/science.272.5263.877
   PubMed Web of Science ®Google Scholar
• Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271:1861-4; PMID:8596954; http://dx.doi.org/10.1126/science.271.5257.1861
   PubMed Web of Science ®Google Scholar
• Rivard N, L'Allemain G, Bartek J, Pouyssegur J. Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J Biol Chem 1996; 271:18337-41; PMID:8702474; http://dx.doi.org/10.1074/jbc.271.31.18337
   PubMed Web of Science ®Google Scholar
• Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J 1996; 15:6595-604; PMID:8978686
   PubMed Web of Science ®Google Scholar
• Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78:67-74; PMID:8033213; http://dx.doi.org/10.1016/0092-8674(94)90573-8
   PubMed Web of Science ®Google Scholar
• Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1:207-14; PMID:10559918; http://dx.doi.org/10.1038/12027
   PubMed Web of Science ®Google Scholar
• Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996; 85:733-44; PMID:8646781; http://dx.doi.org/10.1016/S0092-8674(00)81239-8
   PubMed Web of Science ®Google Scholar
• Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85:707-20; PMID:8646779; http://dx.doi.org/10.1016/S0092-8674(00)81237-4
   PubMed Web of Science ®Google Scholar
• Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396:177-80; PMID:9823898; http://dx.doi.org/10.1038/24179
   PubMed Web of Science ®Google Scholar
• Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3:222-5; PMID:9018243; http://dx.doi.org/10.1038/nm0297-222
   PubMed Web of Science ®Google Scholar
• Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3:227-30; PMID:9018244; http://dx.doi.org/10.1038/nm0297-227
   PubMed Web of Science ®Google Scholar
• Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nat Med 1997; 3:593; PMID:9176477; http://dx.doi.org/10.1038/nm0697-593
   PubMed Web of Science ®Google Scholar
• Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Nat Acad Sci U S A 1997; 94:6380-5; PMID:9177226
   PubMed Web of Science ®Google Scholar
• Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997; 57:1259-63; PMID:9102210
   PubMed Web of Science ®Google Scholar
• Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, Mikata A, Harigaya K, Kuriyama T. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol 1998; 153:505-13; PMID:9708810; http://dx.doi.org/10.1016/S0002-9440(10)65593-9
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994; 79:573-82; PMID:7954824; http://dx.doi.org/10.1016/0092-8674(94)90543-6
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Balbin M, Pendas AM, Vizoso F, Velasco G, Lopez-Otin C. Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum Genet 1996; 97:91-4; PMID:8557269; http://dx.doi.org/10.1007/BF00218840
   PubMed Web of Science ®Google Scholar
• Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, et al. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995; 55:1211-4; PMID:7882310
   PubMed Web of Science ®Google Scholar
• Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995; 55:1206-10; PMID:7882309
   PubMed Web of Science ®Google Scholar
• Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995; 55:2266-9; PMID:7757974
   PubMed Web of Science ®Google Scholar
• Kawamata N, Seriu T, Koeffler HP, Bartram CR. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas. Cancer 1996; 77:570-5; PMID:8630967; http://dx.doi.org/10.1002/(SICI)1097-0142(19960201)77:3<570::AID-CNCR21>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M, Koeffler HP. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995; 86:1924-30; PMID:7655021
   PubMed Web of Science ®Google Scholar
• Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP. p27/Kip1 mutation found in breast cancer. Cancer Res 1996; 56:2400-4; PMID:8625318
   PubMed Web of Science ®Google Scholar
• Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res 1996; 56:1413-7; PMID:8640833
   PubMed Web of Science ®Google Scholar
• Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997; 16:5334-44; PMID:9311993; http://dx.doi.org/10.1093/emboj/16.17.5334
   PubMed Web of Science ®Google Scholar
• Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11:1464-78; PMID:9192873; http://dx.doi.org/10.1101/gad.11.11.1464
   PubMed Web of Science ®Google Scholar
• Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1:193-9; PMID:10559916; http://dx.doi.org/10.1038/12013
   PubMed Web of Science ®Google Scholar
• De Vita F, Riccardi M, Malanga D, Scrima M, De Marco C, Viglietto G. PKC-dependent phosphorylation of p27 at T198 contributes to p27 stabilization and cell cycle arrest. Cell Cycle 2012; 11:1583-92; PMID:22441823; http://dx.doi.org/10.4161/cc.20003
   PubMed Web of Science ®Google Scholar
• Ishida N, Kitagawa M, Hatakeyama S, Nakayama K. Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability. J Biol Chem 2000; 275:25146-54; PMID:10831586; http://dx.doi.org/10.1074/jbc.M001144200
   PubMed Web of Science ®Google Scholar
• Penas C, Ramachandran V, Simanski S, Lee C, Madoux F, Rahaim RJ, Chauhan R, Barnaby O, Schurer S, Hodder P, et al. Casein kinase 1delta-dependent Wee1 protein degradation. J Biol Chem 2014; 289:18893-903; PMID:24817118; http://dx.doi.org/10.1074/jbc.M114.547661
   PubMed Web of Science ®Google Scholar
• Verma R, Peters NR, D'Onofrio M, Tochtrop GP, Sakamoto KM, Varadan R, Zhang M, Coffino P, Fushman D, Deshaies RJ, et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 2004; 306:117-20; PMID:15459393; http://dx.doi.org/10.1126/science.1100946
   PubMed Web of Science ®Google Scholar
• Penas C, Ramachandran V, Simanski S, Lee C, Madoux F, Rahaim RJ, Chauhan R, Barnaby O, Schurer S, Hodder P, et al. Casein kinase 1delta-dependent Wee1 protein degradation. J Biol Chem 2014; 289:18893-903; PMID:24817118; http://dx.doi.org/10.1074/jbc.M114.547661
   PubMed Web of Science ®Google Scholar
• Madoux F, Simanski S, Chase P, Mishra JK, Roush WR, Ayad NG, Hodder P. An ultra-high throughput cell-based screen for wee1 degradation inhibitors. J Biomol Screen 2010; 15:907-17; PMID:20660794; http://dx.doi.org/10.1177/1087057110375848
   PubMed Web of Science ®Google Scholar
• Herman AG, Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C, Stockwell BR. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov 2011; 1:312-25; PMID:22586610; http://dx.doi.org/10.1158/2159-8290.CD-11-0104
   PubMed Web of Science ®Google Scholar
• Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, Kaelin WG Jr. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 2004; 10:643-8; PMID:15122251; http://dx.doi.org/10.1038/nm1047
   PubMed Web of Science ®Google Scholar
• Schurer SC, Muskal SM. Kinome-wide activity modeling from diverse public high-quality data sets. J Chem Inform Model 2013; 53:27-38; PMID:23259810; http://dx.doi.org/10.1021/ci300403k
   PubMed Web of Science ®Google Scholar
• Ballester R, Rosen OM. Fate of immunoprecipitable protein kinase C in GH3 cells treated with phorbol 12-myristate 13-acetate. J Biol Chem 1985; 260:15194-9; PMID:3905792
   PubMed Web of Science ®Google Scholar
• Nishizuka Y, Nakamura S. Lipid mediators and protein kinase C for intracellular signalling. Clin Exp Pharmacol Physiol Suppl 1995; 22:S202-3; PMID:9072357; http://dx.doi.org/10.1111/j.1440-1681.1995.tb02883.x
   PubMedGoogle Scholar
• Ryves WJ, Harwood AJ. The interaction of glycogen synthase kinase-3 (GSK-3) with the cell cycle. Prog Cell Cycle Res 2003; 5:489-95; PMID:14593744
   PubMedGoogle Scholar
• Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001; 276:251-60; PMID:11013232; http://dx.doi.org/10.1074/jbc.M002466200
   PubMed Web of Science ®Google Scholar
• Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene 2001; 20:3786-97; PMID:11439342; http://dx.doi.org/10.1038/sj.onc.1204503
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511; PMID:9832503; http://dx.doi.org/10.1101/gad.12.22.3499
   PubMed Web of Science ®Google Scholar
• Kunick C, Lauenroth K, Leost M, Meijer L, Lemcke T. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett 2004; 14:413-6; PMID:14698171; http://dx.doi.org/10.1016/j.bmcl.2003.10.062
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochimica et Biophysica Acta 2002; 1593:45-55; PMID:12431783; http://dx.doi.org/10.1016/S0167-4889(02)00347-6
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Research: MCR 2007; 5:909-22; PMID:17855660; http://dx.doi.org/10.1158/1541-7786.MCR-06-0388
   PubMed Web of Science ®Google Scholar
• Wang Z, Petersen K, Weaver MS, Magnuson NS. cDNA cloning, sequencing and characterization of bovine pim-1. Vet Immunol Immunopathol 2001; 78:177-95; PMID:11182156; http://dx.doi.org/10.1016/S0165-2427(00)00259-2
   PubMed Web of Science ®Google Scholar
• Tahara E, Kadara H, Lacroix L, Lotan D, Lotan R. Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol Ther 2009; 8:801-7; PMID:19333010; http://dx.doi.org/10.4161/cbt.8.9.8186
   PubMed Web of Science ®Google Scholar
• Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 2004; 6:1229-35; PMID:15531880; http://dx.doi.org/10.1038/ncb1194
   PubMed Web of Science ®Google Scholar
• Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003; 371:199-204; PMID:12534346; http://dx.doi.org/10.1042/BJ20021535
   PubMed Web of Science ®Google Scholar
• Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1:60-7; PMID:10559866; http://dx.doi.org/10.1038/9035
   PubMed Web of Science ®Google Scholar
• Banerjee S, Lu J, Cai Q, Sun Z, Jha HC, Robertson ES. EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation. PLoS Pathogens 2014; 10:e1004304; PMID:25121590; http://dx.doi.org/10.1371/journal.ppat.1004304
   PubMed Web of Science ®Google Scholar
• Schurer SC, Vempati U, Smith R, Southern M, Lemmon V. BioAssay ontology annotations facilitate cross-analysis of diverse high-throughput screening data sets. J Biomol Scr 2011; 16:415-26; PMID:21471461; http://dx.doi.org/10.1177/1087057111400191
   PubMed Web of Science ®Google Scholar
• Vempati UD, Przydzial MJ, Chung C, Abeyruwan S, Mir A, Sakurai K, Visser U, Lemmon VP, Schürer SC. Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO). PloS One 2012; 7:e49198; PMID:23155465; http://dx.doi.org/10.1371/journal.pone.0049198
   PubMed Web of Science ®Google Scholar